Kang Fu
Junzhe Su
Yiming Zhou
Xiaotong Chen
Xiao Hu
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
- Department of Hepatobiliary Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China
by Fu K, Su J, Zhou Y, Chen X and Hu X (2024). Front. Pharmacol. 15:1498031. doi: 10.3389/fphar.2024.1498031
In the published article, there was an error in Figure 13 as published. Due to a data format inconsistency between CSV and TXT files during analysis, an undetected empty row in the header resulted in a misalignment of data. This affected the gene names on the y-axis and cell types on the x-axis, causing a one-row shift in visualization, which led to incorrect matching of color representation with corresponding samples. The corrected Figure 13 and its caption appear below.
Figure 13
Figure 13. Differential expression analysis of prognostic genes in pancreatic cell lines (A–E). The relative mRNA expression levels of KRTCAP2, NENF, PSAP, MRPL41, and S100A16 were quantified by qRT-PCR in pancreatic cancer cell line PANC-1 and normal pancreatic epithelial cell line hTERT-HPNE.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: pancreatic ductal adenocarcinoma, epigenetic regulation, single-cell RNA sequencing, machine learning, prognostic model, tumor microenvironment, drug sensitivity
Citation: Fu K, Su J, Zhou Y, Chen X and Hu X (2025) Corrigendum: The role of epigenetic regulation in pancreatic ductal adenocarcinoma progression and drug response: an integrative genomic and pharmacological prognostic prediction model. Front. Pharmacol. 16:1560529. doi: 10.3389/fphar.2025.1560529
Received: 14 January 2025; Accepted: 27 January 2025;
Published: 18 February 2025.
Edited and reviewed by:
Dawei Chen, University of Kiel, GermanyCopyright © 2025 Fu, Su, Zhou, Chen and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xiao Hu, aHV4aWFvMjAyQDE2My5jb20=
†These authors have contributed equally to this work